Cronos Group Inc. logo

Cronos Group Inc. (CRON)

Market Closed
1 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
3. 38
+0.01
+0.2967%
After Hours
$
3. 44
+0.06 +1.7751%
1.26B Market Cap
- P/E Ratio
- Div Yield
1.11M Volume
- Eps
$ 3.37
Previous Close
Add Transaction
Day Range
3.33 3.42
Year Range
2.28 3.61
Want to track CRON and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CRON closed today higher at $3.38, an increase of 0.2967% from yesterday's close, completing a monthly increase of 19.0141% or $0.54. Over the past 12 months, CRON stock gained 28.0303%.
CRON is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2026, missed the consensus estimates by -0.02%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

CRON Chart

People also search for

Alvotech SA
$ 5.24
+0.9634%
Ani Pharmaceuticals Inc.
$ 71.92
-1.8157%
Alliant Energy Corporation
$ 86.45
-8.0417%
Phibro Animal Health Corporation
$ 38.37
+1.6693%
Harrow Inc.
$ 36.97
+0.1626%
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock

Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock

Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks | 2 weeks ago
Cronos Group Q2 Earnings Call Highlights

Cronos Group Q2 Earnings Call Highlights

Cronos Group NASDAQ: CRON reported record second-quarter net revenue, gross profit and adjusted EBITDA for 2026, supported by growth in Israel, Canada and other international markets, including Germany.

Marketbeat | 3 weeks ago
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates

Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates

Cronos Group (CRON) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.1 per share a year ago.

Zacks | 3 weeks ago

Cronos Group Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Curtis Ellergodt
Curtis Ellergodt Rothschild Investment LLC
62 $130 $175.46 $45.46 34.97%
BZ
Brandon Zatopek Commonwealth Equity Services LLC
39,716 $110,407 $123,119.6 $12,712.6 11.51%
JD
Jim Dushek HARBOUR INVESTMENTS Inc.
2,568 $6,445.68 $7,909.44 $1,463.76 22.71%
NA
Nizar Araji National Bank Of Canada /FI/
21,566 $54,726.28 $66,854.6 $12,128.32 22.16%
BR
Bill Reuther SILVER OAK SECURITIES Inc.ORPORATED
655,972 $1.81M $2.03M $220,293.84 12.15%

Cronos Group Inc. (CRON) FAQ

What is the stock price today?

The current price is $3.38.

On which exchange is it traded?

Cronos Group Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is CRON.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.26B.

Has Cronos Group Inc. ever had a stock split?

No, there has never been a stock split.

Cronos Group Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Michael Ryan Gorenstein CEO
NASDAQ (NMS) Exchange
22717L101 CUSIP
CA Country
610 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Cronos Group Inc. stands as a pioneering entity in the cannabinoid industry, dedicating its efforts to the cultivation, production, and distribution of cannabis products across notable markets in Canada, Israel, and Germany. Since its establishment in 2012, the company has positioned itself in Toronto, Canada, navigating the complexities of the ever-evolving cannabis landscape. Through strategic brand development and an unwavering commitment to quality, Cronos Group has carved a niche for itself, becoming synonymous with excellence in the realm of cannabinoid offerings.

Products and Services

  • Dried Flower: Cronos Group offers a variety of premium dried cannabis flowers, catering to the traditional cannabis consumer. These products are carefully cultivated to ensure the highest quality and potency, meeting the diverse preferences and needs of their clientele.
  • Pre-rolls: For those seeking convenience without compromising on quality, Cronos Group's pre-rolled cannabis offers an easy-to-use option. Expertly rolled from their top-quality dried flower, these pre-rolls provide a consistent and satisfying experience for both new and seasoned users.
  • Oils: Cannabis oils by Cronos Group are extracted using state-of-the-art techniques to ensure purity and potency. These oils are versatile, designed for consumptions such as ingestion or topical application, catering to a wide range of medicinal and recreational uses.
  • Vaporizers: Recognizing the growing demand for smoke-free alternatives, Cronos Group offers high-quality cannabis vaporizers. These devices are designed for convenient and discreet use, providing a modern approach to cannabis consumption.
  • Edibles: Catering to the evolving tastes of their consumer base, Cronos Group has ventured into the world of cannabis-infused edibles. This range includes various ingestible forms, offering a delicious and controlled way to experience the effects of cannabis.
  • Cannabis Tinctures: For those preferring direct ingestion or alternative application methods, Cronos Group's cannabis tinctures offer a potent and precise dosing solution. These liquid extracts can be consumed directly or mixed with food or drinks, providing flexibility in usage.

The product lineup is marketed under distinguished brands such as Spinach, Lord Jones, and PEACE NATURALS, each carrying a unique identity and clientele focus, thus allowing Cronos Group to cater to a broad spectrum of consumer needs and preferences.

Contact Information

Address: 4491 Concession Road 12
Phone: 14165040004